These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 5126994)

  • 1. Tyrosine metabolism: urinary excretion studies in Parkinsonism.
    Szpunar WE; Ericsson AD; McCann DS
    Clin Chim Acta; 1971 Nov; 35(1):209-17. PubMed ID: 5126994
    [No Abstract]   [Full Text] [Related]  

  • 2. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 3. A simple and rapid gas chromatography for determining 3,4-dihydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid in urine from patients with parkinsonism treated with L-3,4-dihydroxyphenylalanine.
    Fukaya J; Imai K; Tamura Z
    Clin Chim Acta; 1971 Jul; 33(2):470-2. PubMed ID: 5119325
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 6. Urinary homogentisic acid: determination by thin-layer chromatography.
    Feldman JM; Bowman J
    Clin Chem; 1973 May; 19(5):459-62. PubMed ID: 4703652
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary excretion of tyrosine metabolites in spina bifida.
    Duckworth T; Bond PA; McKibbin B; Mitchell EC
    Clin Chim Acta; 1973 Jan; 43(2):249-55. PubMed ID: 4570105
    [No Abstract]   [Full Text] [Related]  

  • 8. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 9. The biochemistry of catecholamines in relation to Parkinson's disease.
    Hinterberger H
    Aust N Z J Med; 1971 May; 1():Suppl 1:14-8. PubMed ID: 5292808
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring phenylalanine-tyrosine metabolism by high-resolution liquid chromatography of urine.
    Mrochek JE; Dinsmore SR; Ohrt DW
    Clin Chem; 1973 Aug; 19(8):927-36. PubMed ID: 4720815
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 14. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 15. Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
    Dziedzic SW; Dziedzic LB; Gitlow SE
    J Lab Clin Med; 1973 Nov; 82(5):829-35. PubMed ID: 4746822
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolism of dopa in Parkinsonism.
    Sandler M; Karoum F; Ruthven CR
    N Engl J Med; 1969 Dec; 281(25):1429. PubMed ID: 5355467
    [No Abstract]   [Full Text] [Related]  

  • 17. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 18. The metabolism of orally administered L-Dopa in Parkinsonism.
    Calne DB; Karoum F; Ruthven CR; Sandler M
    Br J Pharmacol; 1969 Sep; 37(1):57-68. PubMed ID: 5343357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of urinary excretion of vanilmandelic and homovanillic acids in cases of neuroblastoma during therapy].
    Lamedica G; Falcone R; De Bernardi B; Canini S
    Minerva Pediatr; 1978 Jan; 30(2):137-46. PubMed ID: 642879
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
    Boulton AA; Marjerrison GL
    Nature; 1972 Mar; 236(5341):76-8. PubMed ID: 4553458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.